Clinical trials show promise in treating central n
Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lym
Source: newswise.com
📰 Patrick Wen News
Patrick Wen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Patrick Wen. Real-time updates on events, politics, business and more.
Black Diamond Therapeutics Presents Promising BDTX-1535
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging...
Source: globenewswire.com
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment ...
Source: marketscreener.com
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with ...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment
Source: eagletribune.com
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data In Patients With Recurrent Glioblastoma At 2024 American Society Of Clinical Onc...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging ant
Source: menafn.com
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass., April 24, 2024 -- Black Diamond Therapeutics, Inc. , a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with...
Source: marketscreener.com
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
Initial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and...
Source: marketscreener.com
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
LA JOLLA, Calif., Nov. 19, 2023 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange , today announced that...
British Columbia Geoff Obrien Patrick Wen Department Of Molecular Medicine Therapeutic Development Center Globenewswire Inc
Source: marketscreener.com
New Vorasidenib Data at SNO 2023 Bolster Servier's Neuro-Oncology Clinical Development Program
/PRNewswire/ -- Servier will showcase new data from its vorasidenib clinical development program in a plenary townhall at the 28th Annual Meeting of the...
Source: prnewswire.com
World No. 3 Ko Jin Young takes the lead at the Aramco Team Series
The world No. 3 and South Korean professional golfer Ko Jin-young took the lead in the Aramco Team Series - following an impressive bogey-fr...
Source: thestandard.com.hk